{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:32:20Z","timestamp":1740148340150,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentre retrospective study including consecutive IBD patients who discontinued anti-TNF due to severe induced skin lesions. Our objectives were to determine factors associated with dermatological remission [complete disappearance of skin lesions] and with IBD relapse in patients with inactive disease at inclusion, notably the impact of an early switch to another biological agent within 3\u00a0months of anti-TNF discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 181 patients [134 women, 160 Crohn\u2019s disease] included in the 13 participating centres, dermatological remission occurred in 110 [62%] patients with a median [interquartile range, IQR] interval of 8.0 [6.8\u201311.0] months. Scalp location was independently associated with less remission of skin lesions (hazard ratio [HR]\u00a0=\u00a00.64 [95% CI 0.43\u20130.94], p\u00a0=\u00a00.02) while early switch was independently associated with a higher probability of remission of skin lesions (HR\u00a0=\u00a01.64 [95% CI 1.1\u20132.5], p\u00a0=\u00a00.02). Among the 148 patients with inactive IBD at inclusion, disease relapse occurred in 75 [51%] patients with a median [IQR] interval of 26.0 [23.0\u201339.1] months. Survival rates without IBD relapse at 1\u00a0year were 85.8% [95% CI 77.5\u201394.9] in the early switch group and 59.3% [95% CI 48.9\u201371.9] in the other group [p\u00a0&amp;lt;\u00a00.01].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Early switch to a new biological is associated with a higher probability of healing of anti-TNF-induced skin lesions and significantly reduces the risk of IBD relapse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac035","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T04:13:26Z","timestamp":1645762406000},"page":"1202-1210","source":"Crossref","is-referenced-by-count":1,"title":["How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study"],"prefix":"10.1093","volume":"16","author":[{"given":"C","family":"Cottron","sequence":"first","affiliation":[{"name":"CHU de Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019H\u00e9pato-gastroent\u00e9rologie et oncologie digestive \u2013 Universit\u00e9 de Bordeaux , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Treton","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD and Nutrition, Beaujon Hospital, APHP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Saint Eloi Hospital, CHU de Montpellier , Montpellier , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-4350","authenticated-orcid":false,"given":"C","family":"Reenaers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU Sart Tilman , Li\u00e8ge , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Amiot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Henri Mondor Hospital, APHP , Creteil , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU de Amiens, and Peritox , UMR I-01 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-6572","authenticated-orcid":false,"given":"L","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, CHRU de Besan\u00e7on , Besan\u00e7on , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Nancy University Hospital, Vandoeuvre les Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bouguen","sequence":"additional","affiliation":[{"name":"CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer) , F-35000 Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Dewit","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Universit\u00e9 Catholique de Louvain Saint Luc , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Nancey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU de Lyon, Lyon Sud Hospital, University Claude Bernard Lyon 1 , INSERM U1111, Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Caillo","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, CHU de N\u00eemes , N\u00eemes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Roblin","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, CHU de Saint-Etienne, Ho\u0302pital Nord, Universite\u0301 Jean Monnet , Saint-Etienne , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saint-Andre\u0301 Hospital, CHU de Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2806","authenticated-orcid":false,"given":"P","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019H\u00e9pato-gastroent\u00e9rologie et oncologie digestive \u2013 Universit\u00e9 de Bordeaux , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Laharie","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Service d\u2019H\u00e9pato-gastroent\u00e9rologie et oncologie digestive \u2013 Universit\u00e9 de Bordeaux , F-33000 Bordeaux , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"2022083014474672300_CIT0001","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"2022083014474672300_CIT0002","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials.","volume":"6","author":"Peyrin\u2013Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022083014474672300_CIT0003","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.","volume":"110","author":"Fr\u00e9ling","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2022083014474672300_CIT0004","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022083014474672300_CIT0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M15-0729","article-title":"Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study.","volume":"164","author":"Cleynen","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022083014474672300_CIT0006","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD.","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022083014474672300_CIT0007","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2022083014474672300_CIT0008","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/MIB.0b013e3182802c07","article-title":"Skin side effects of inflammatory bowel disease therapy.","volume":"19","author":"Torres","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022083014474672300_CIT0009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment.","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"2022083014474672300_CIT0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s10620-018-4921-y","article-title":"Anti-tumor necrosis factor-\u03b1-induced dermatological complications in a large cohort of inflammatory bowel disease patients.","volume":"63","author":"Andrade","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2022083014474672300_CIT0011","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study.","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022083014474672300_CIT0012","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/1346-8138.14816","article-title":"Ustekinumab for skin reactions associated with anti-tumor necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: a single-center retrospective study.","volume":"46","author":"Ezzedine","year":"2019","journal-title":"J Dermatol"},{"key":"2022083014474672300_CIT0013","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.dld.2016.08.122","article-title":"Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.","volume":"48","author":"Pijls","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2022083014474672300_CIT0014","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications.","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022083014474672300_CIT0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The First European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2022083014474672300_CIT0016","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"2022083014474672300_CIT0017","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor [anti-TNF] therapy in inflammatory bowel disease: a single academic centre case series.","volume":"8","author":"Afzali","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022083014474672300_CIT0018","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"2022083014474672300_CIT0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"2022083014474672300_CIT0020","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022083014474672300_CIT0021","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2340\/00015555-2636","article-title":"Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors.","volume":"97","author":"Darrigade","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2022083014474672300_CIT0022","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.dld.2019.03.007","article-title":"Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study.","volume":"51","author":"Pugliese","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2022083014474672300_CIT0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.","volume":"54","author":"Bots","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2022083014474672300_CIT0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis.","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022083014474672300_CIT0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/apt.16361","article-title":"Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.","volume":"53","author":"Casanova","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2022083014474672300_CIT0026","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13276","article-title":"Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.","volume":"42","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022083014474672300_CIT0027","article-title":"Prediction","author":"Pauwels","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac035\/42953003\/jjac035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/8\/1202\/45625763\/jjac035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/8\/1202\/45625763\/jjac035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T14:48:35Z","timestamp":1661870915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/8\/1202\/6537448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,26]]},"published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac035","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"type":"print","value":"1873-9946"},{"type":"electronic","value":"1876-4479"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,2,26]]}}}